Free Trial

Taysha Gene Therapies (TSHA) Stock Forecast & Price Target

$2.97
-1.06 (-26.30%)
(As of 06/18/2024 ET)

Taysha Gene Therapies - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$7.00
135.69% Upside
High Forecast$9.00
Average Forecast$7.00
Low Forecast$5.00
TypeCurrent Forecast
6/20/23 to 6/19/24
1 Month Ago
5/21/23 to 5/20/24
3 Months Ago
3/22/23 to 3/21/24
1 Year Ago
6/20/22 to 6/20/23
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.00$7.00$6.57$7.58
Forecasted Upside135.69% Upside160.98% Upside149.73% Upside415.82% Upside
Get Taysha Gene Therapies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.

TSHA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TSHA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Taysha Gene Therapies Stock vs. The Competition

TypeTaysha Gene TherapiesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside135.69% Upside1,068.17% Upside11.30% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/18/2024Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00+135.69%
6/17/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00+76.32%
5/28/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00+115.38%
5/14/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Buy$2.00 ➝ $8.00+233.33%
4/9/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$9.00+235.82%
3/21/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$7.00+126.54%
3/20/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$5.00+87.27%
9/20/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$6.00 ➝ $5.00+62.87%
8/15/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$6.00 ➝ $8.00+275.59%
2/2/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$23.00 ➝ $3.00+62.16%
1/4/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$14.00 ➝ $10.00+354.54%
11/9/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/8/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$22.00 ➝ $19.00+775.57%
8/12/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$9.00 ➝ $5.00+26.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:13 AM ET.

TSHA Forecast - Frequently Asked Questions

What is Taysha Gene Therapies's stock forecast and purchase recommendation?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Taysha Gene Therapies is $7.00, with a high forecast of $9.00 and a low forecast of $5.00. The consensus rating for Taysha Gene Therapies stock is Buy based on the current 9 buy ratings for TSHA. Learn more on TSHA's analyst rating history.

Do Wall Street analysts like Taysha Gene Therapies more than its competitors?

Analysts like Taysha Gene Therapies more than other "medical" companies. The consensus rating for Taysha Gene Therapies is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TSHA compares to other companies.

Does Taysha Gene Therapies's stock price have much upside?

According to analysts, Taysha Gene Therapies's stock has a predicted upside of 140.18% based on their 12-month stock forecasts.

What analysts cover Taysha Gene Therapies?

Taysha Gene Therapies has been rated by research analysts at Canaccord Genuity Group, Cantor Fitzgerald, Chardan Capital, Jefferies Financial Group, Needham & Company LLC, and Piper Sandler in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:TSHA) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners